Description: Learn about JEVTANA, a NCCN designated category 1 second-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. See Important Safety Information and full Prescribing Information, including boxed WARNING.
For US Healthcare Professionals Only
For your mCRPC patients after docetaxel
SEIZE THE WINDOW OF OPPORTUNITY